- NCIt
- C4615
Loading cancer entity…
Loading cancer entity…
Clinical trials
11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07301424 | Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL | not yet recruiting | Phase 2 | 80 | University of AlbertaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00984217 | Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Jan 8, 2016 | clinicaltrials |
| NCT01221376 | Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) | unknown | Phase 2 | 20 | Renato MelaragnoOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT01222013 | Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) |
Data updated 22 days agoSource updated Aug 12, 2026source: clinicaltrials
| suspended |
| Phase 2 |
| 20 |
| Renato MelaragnoOTHER |
| 0 |
| Mar 26, 2013 |
| clinicaltrials |